The primary role of this medication is to provide supportive relief in situations involving certain distressing symptoms linked to severe headache episodes. As an abortive treatment, it is applied for the management of acute migraine attacks (with or without aura) and is commonly used to help with acute cluster headache episodes in adults.

This treatment is generally used for managing symptoms that become more disruptive during flare-ups, applied in addressing the severe pain intensity, and is considered relevant when symptoms escalate temporarily and short-term symptomatic assistance is needed. The specific indications for which this medication is relevant include migraine with aura, migraine without aura, and acute cluster headache.

It also helps address symptom clusters that may become intense or disruptive, such as nausea, vomiting, and heightened sensitivity to external factors like light and sound. Managing these associated manifestations provides supportive relief when symptoms interfere with daily functioning and contributes to easing the overall symptom load.

The core patient benefit is symptomatic relief that helps patients cope more steadily with difficult episodes. This support contributes to improved comfort during periods of heightened symptoms and may help maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Acute Neuro-Headache Pain The medication is applied in addressing the symptoms associated with the acute, severe phase of headache episodes, supporting patients during episodes of heightened discomfort.

Regulatory References

1. NIH summary of therapeutic use

Population Eligibility and Contraindications

Амигрен (Sumatriptan Succinate) is approved for use primarily in adults between the ages of 18 and 65 with a confirmed diagnosis of the specified acute headache episodes. Official regulatory documents strictly define populations who can and cannot use this medicine.

---

Absolute Contraindications (Must Not Be Used)

Use is contraindicated in patients with a history of Ischemic Coronary Artery Disease (CAD), including myocardial infarction or angina, uncontrolled hypertension, or a history of Stroke or Transient Ischemic Attack (TIA). Patients with Hemiplegic or Basilar Migraine and those with Severe Hepatic Impairment are also excluded. Use is prohibited when taken with ergotamine-containing medicines or other triptans (within 24 hours) and MAO-A inhibitors (within two weeks).

---

Age and Condition Restrictions

Safety and efficacy have not been established for use in children and adolescents under 18 years, and use is generally not recommended. Use in older adults over 65 years is also not recommended due to limited experience and requires a mandatory pre-treatment cardiovascular evaluation. For pregnant or breastfeeding women, the medicine should only be considered if the potential benefit justifies the potential risk, as the compound is known to be excreted in breast milk. Patients with mild to moderate hepatic impairment may be permitted to use the medicine but require a restricted dose.

Interactions with other medicines and products

Official regulatory documentation identifies several classes of medicinal products that interact with Амигрен (Sumatriptan Succinate), establishing specific administration constraints and prohibitions.

Contraindicated Combinations and Exposure Risk

Co-administration with Monoamine Oxidase A (MAO-A) inhibitors is formally contraindicated. This restriction is a result of a pharmacokinetic interaction where MAO-A inhibitors prevent the metabolic clearance of Sumatriptan, leading to a significant increase in its plasma concentration and overall exposure. A mandatory period of 14 days must pass after discontinuing an MAO-A inhibitor before Sumatriptan may be administered.

Also contraindicated is co-use with Ergotamine-containing products or Ergot-type derivatives (such as Methysergide). This is based on a pharmacodynamic interaction that heightens the risk of additive and prolonged vasoconstrictive effects.

Pharmacodynamic and Timing Constraints

Administration restrictions apply when combining Sumatriptan with other serotonergic agents or vasoconstrictors. Co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) carries the documented risk of developing Serotonin Syndrome due to additive central serotonergic effects.

Furthermore, Sumatriptan must not be administered within 24 hours of taking any Ergotamine product or another 5-HT1 agonist (triptan) due to the risk of additive pharmacodynamic effects.

Targeted Agonism of Peripheral Serotonin Receptors

The mechanism of action centers on selective activation (agonism) of the serotonin 5- HT1 B and 5- HT1 D receptors. These G-protein coupled receptors are located peripherally on the cranial blood vessels and the terminals of the trigeminal nerve. By engaging these targets, the drug initiates two distinct physiological responses required to modulate the neurovascular signaling associated with the acute state.

---

Dampening of Neurogenic Inflammation and Vasoconstriction

The drug simultaneously modulates two key pathways. Activation of the 5- HT1 B receptors causes a targeted contraction (vasoconstriction) of cranial blood vessels. Concurrently, activation of the 5- HT1 D receptors on nerve endings suppresses the release of vasodilatory and pro-inflammatory neuropeptides, such as Calcitonin Gene-Related Peptide ( CGRP). This combined molecular o physiological effect leads to a modulation of the cranial vascular tone and a modulation of the nociceptive signaling cascade.

---

️ Mechanistic Limitations

This specific biological mechanism is defined by its mechanism as an acute pathway modulator. Because it focuses on modulating the established neurovascular dysregulation, it does not possess a mechanism that alters the underlying neural excitability patterns or processes necessary for sustained modulation of baseline neural excitability patterns.

Administration Routes and Dosing

Амигрен is indicated for use through multiple administration routes to manage acute episodes. The medication is available as an oral tablet, a solution for subcutaneous (SC) injection, and formulations for intranasal delivery. This versatility in route is necessary for timely delivery during an acute episode, allowing use when oral intake may be challenging. The medication is utilized strictly for the acute treatment of an event that has already begun, and it is not intended for a prophylactic, or preventive, regimen.

For oral administration, a single dose typically ranges from 25 mg to 100 mg, with the cumulative maximum dose allowed not to exceed 200 mg within a 24-hour period. Oral tablets may be administered independent of meals, either with or without food. The SC injection form is administered as a 4 mg or 6 mg single dose, with a maximum limit of 12 mg over a 24-hour period.

Frequency and Timing Protocol

The minimum time interval between any two subcutaneous doses is defined as one hour, while the interval for oral tablets is two hours. A crucial part of the usage instruction involves the timing of subsequent doses. If the initial dose provides relief but symptoms return (recur), a second dose is permissible only after observing the route-specific minimum time interval. Conversely, if the first dose fails entirely to provide any initial relief, it is not recommended to take a second dose for the same episode. Specific administration rules exist for certain populations; for instance, the maximum single oral dose for patients with mild to moderate hepatic impairment is restricted to 50 mg.

Research Evidence: Overview of Studies

Summary of Key Findings

Studies have examined the compound as a therapeutic avenue. Research has explored the compound’s association with changes in the frequency and severity of migraine attacks.

• Randomized controlled trials (RCTs) have evaluated the compound’s effect on patient outcomes across diverse groups.
• Research primarily focused on adult populations in its evaluation.
• Long-term open-label extension studies provided data on the durability of observed effects over extended periods and on the safety profile.

---

Research Focus on Characteristics

Research evaluated the compound by focusing on its ability to interact with specific physiological targets.

• Studies have explored the compound’s characteristics, including observed time to changes in pain.

---

Efficacy Data

Acute Treatment Efficacy

Initial efficacy studies evaluated the compound for its effect on pain freedom at 2 hours and most bothersome symptom (MBS) freedom at 2 hours.

• The research findings included a measurement of the proportion of participants who experienced pain and MBS freedom at the 2-hour mark, comparing groups that received the compound to those that received placebo.
• The trial observations were reported as generally consistent when measured across different levels of attack severity.

Preventive Treatment Efficacy

Preventive studies evaluated the change in mean monthly migraine days (MMDs) from baseline.

• The primary endpoint in most trials was the change in MMDs over a 12-week treatment period.
• Secondary endpoints included the proportion of patients who achieved a 50% or greater reduction in MMDs.

---

Combination and Off-Label Studies

Combination studies evaluated whether co-administering this compound with standard acute treatments differed from monotherapy alone.

• Findings from these studies have been used to evaluate the compound when co-administered alongside traditional acute medications.
• The use of the compound in other headache disorders is not yet supported by extensive, conclusive evidence, and large-scale, controlled trials are ongoing to investigate effects in cluster headaches and chronic tension-type headaches.

---

Safety and Tolerability

The safety profile was characterized across Phase 2 and Phase 3 trials. Reported adverse events (AEs) were described within the research as primarily mild or moderate in severity.

• Reported AEs most frequently included nasopharyngitis, upper respiratory tract infection, and nausea.
• Discontinuation rates due to AEs were reported as low and comparable between the compound and placebo groups in most trials.
• The influence of alcohol use during treatment has been a focus of some safety studies.

Common questions about Амигрен (FAQ)

Q: Is Амигрен used for tension headaches or only migraines?

A: According to regulatory documents, the medication is specifically indicated for the acute treatment of migraine attacks in adults, which may occur with or without an aura. The injectable form is also indicated for cluster headaches. Official product information states that this medication should not be used to treat common tension headaches.

Q: Does Амигрен cause drowsiness, and should I avoid driving after taking it?

A: Official product information lists drowsiness and dizziness as commonly reported side effects. Because these effects may impact mental alertness, official product information notes that any activities requiring full concentration should be approached with caution until the user is certain how they respond to the medicine.

Q: How long does it usually take for Амигрен to start working?

A: Studies examining the effectiveness of the medication typically measure patient outcomes like pain freedom and significant relief at the two-hour mark after administration. This two-hour time point is a key metric used in clinical trials to evaluate the drug's acute therapeutic effect.

Q: Is there a maximum number of days per month someone should use Амигрен?

A: Regulatory guidelines address the risk of Medication Overuse Headache (MOH), sometimes known as rebound headache. To reduce this risk, the safety of using the medication to treat an average of more than four headaches in a 30-day period has not been established in clinical research.

Q: Is Амигрен generally considered safe for long-term, occasional use?

A: The medication is designed for acute treatment and is not intended for regular use. Excessive or prolonged use is formally associated with the development of Medication Overuse Headache (MOH). For individuals using the drug only occasionally, official studies have examined the long-term safety profile.

Q: Why do some people experience tingling or flushing after taking Амигрен?

A: Tingling, flushing, warmth, and sensations of pressure or tightness, often felt in the chest or neck, are listed as commonly observed adverse reactions in official documents. These are generally transient sensory disturbances that occur shortly after the medication is administered.

Q: Is the research evidence for Амигрен based on many large studies?

A: Official documents confirm that the efficacy of the compound has been demonstrated across multiple randomized, double-blind, placebo-controlled clinical studies. The safety and effectiveness profile has also been characterized through long-term open-label extension studies.

Q: Is it true that Амигрен is only effective if taken early in the migraine attack?

A: Official administration guidance indicates that while the medication may be administered as soon as the symptoms of a migraine attack start, it is generally permissible to take it at any time during the attack. The goal is to interrupt the acute physiological processes of the event.

Q: What happens if I take Амигрен and my headache turns out not to be a migraine?

A: Regulatory warnings state that the medication should only be used to treat confirmed headache episodes. If a headache is not a migraine, using this medication may lead to serious adverse reactions if the underlying cause is a different condition, such as a cerebrovascular event like a stroke.

Q: Can Амигрен affect a person's mood or cause anxiety?

A: Official adverse reaction lists include anxiety and depression as less common effects. Additionally, agitation is documented as a symptom associated with the rare risk of Serotonin Syndrome, which is an interaction risk with certain other medications.

Q: What is the experience of people using Амигрен who have asthma?

A: Official regulatory documents list asthma as an infrequent adverse reaction reported in the respiratory system category. It is not generally listed as a contraindication in the official product information.

Q: Has there been research on the use of Амигрен during the initial signs of a migraine aura?

A: The medication is formally indicated for the acute treatment of migraine attacks that occur with or without aura. This confirms that research and authorization cover its use in attacks where the initial aura phase may be present.

Q: Does Амигрен interact with common herbal supplements like St. John's Wort?

A: Regulatory drug interaction warnings state that co-administering this medication with St. John’s Wort may increase the risk of developing Serotonin Syndrome. This combination is listed as a serious interaction risk in official labeling.

Q: What does 'contraindicated' mean in the context of who cannot use Амигрен?

A: The term 'contraindicated' is used in official regulatory documents to identify situations in which the medication must not be used because the risk of serious harm outweighs any potential benefit. This includes patients with pre-existing conditions, such as coronary artery disease or uncontrolled high blood pressure.

Q: What should I do if I accidentally take two doses of Амигрен too close together?

A: Regulatory documents warn that exceeding the maximum recommended dosage within a 24-hour period can lead to overdose symptoms. The product information states that immediate medical assistance should be sought in this situation.

Q: Can Амигрен be used to treat other types of chronic pain?

A: Official regulatory indications state that the medication is approved for the acute treatment of specific headache attacks only. It does not possess a mechanism of action that makes it suitable for the management or treatment of other types of chronic pain.

Q: Is Амигрен available without a prescription?

A: Official labeling categorizes the medication as a human prescription drug. It is not generally available as an over-the-counter treatment.

Q: What is the duration of the effect of a single dose of Амигрен?

A: In clinical pharmacology, the elimination half-life is the measure of how long it takes for half of the active substance to be cleared from the body. For this medication, the elimination half-life is approximately 2.5 hours.

Q: Does the package insert for Амигрен define which symptoms require immediate medical attention?

A: Yes, official patient counseling information explicitly defines specific symptoms that may indicate a serious adverse reaction, such as sudden and severe chest pain, signs of a stroke, or signs of a serious allergic reaction (anaphylaxis). The product information states that these symptoms require immediate medical attention.

Q: Does Амигрен have any effects on blood sugar levels?

A: Official adverse reaction reports list both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar) as rare occurrences within the Endocrine and Metabolic system category.

Q: Can people with kidney problems use Амигрен?

A: Regulatory warnings indicate that caution should be used when the medication is administered to patients with impaired renal (kidney) function. This is because the drug's main metabolite is largely eliminated from the body through the kidneys.

Q: Is it normal to feel a temporary change in taste after taking Амигрен?

A: A temporary change in taste is listed in regulatory documents as a rare side effect of the medication. An unusual or unpleasant taste may occur specifically after using the nasal spray formulation.

Q: How long does Амигрен stay in your system?

A: The official pharmacokinetic data for the active substance indicates an elimination half-life of approximately 2.5 hours. This is the time it takes for the concentration of the medication in the body to drop by half.

How to Store and Dispose of Amigren (Sumatriptan Succinate)

Official labeling requires Amigren to be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). The product must be protected from light and moisture and kept in its original, tightly closed container.

Handling and Child Safety

The medication must not be refrigerated or frozen. It is mandatory to keep the product out of the sight and reach of children.

Disposal Requirements

Disposal of unused or expired Amigren must follow local regulations; the product should not be thrown in household trash or poured into wastewater. Used needles, syringes, and auto-injector devices (sharps) must be placed immediately into an FDA-cleared sharps disposal container.